|
Report Date : |
20.12.2013 |
IDENTIFICATION DETAILS
|
Name : |
CFR CORPORACION FARMACEUTICA RECALCINE |
|
|
|
|
Registered Office : |
Pedro de Valdivia 295, Providencia, Santiago |
|
|
|
|
Country : |
Chile |
|
|
|
|
Date of Incorporation : |
Not Available |
|
|
|
|
Line of Business : |
Wholesale Trade-Non-Durable Goods. (Papers, Perfumes, drugs, hardware,
Groceries, apparel, food, dairy products, beverages.) |
|
|
|
|
No. of Employees : |
Not Available |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made on
e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March, 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Chile |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHILE - ECONOMIC OVERVIEW
Chile has a market-oriented economy characterized by a high level of foreign trade and a reputation for strong financial institutions and sound policy that have given it the strongest sovereign bond rating in South America. Exports account for approximately one-third of GDP, with commodities making up some three-quarters of total exports. Copper alone provides 19% of government revenue. From 2003 through 2012, real growth averaged almost 5% per year, despite the slight contraction in 2009 that resulted from the global financial crisis. Chile deepened its longstanding commitment to trade liberalization with the signing of a free trade agreement with the US, which took effect on 1 January 2004. Chile has 22 trade agreements covering 60 countries including agreements with the European Union, Mercosur, China, India, South Korea, and Mexico. Chile has joined the United States and nine other countries in negotiating the Trans-Pacific-Partnership trade agreement. In 2012, foreign direct investment inflows reached $28.2 billion, an increase of 63% over the previous record set in 2011. The Chilean Government has generally followed a countercyclical fiscal policy, accumulating surpluses in sovereign wealth funds during periods of high copper prices and economic growth, and generally allowing deficit spending only during periods of low copper prices and growth. As of 31 December 2012, those sovereign wealth funds - kept mostly outside the country and separate from Central Bank reserves - amounted to more than $20.9 billion. Chile used these funds to finance fiscal stimulus packages during the 2009 economic downturn. In May 2010 Chile signed the OECD Convention, becoming the first South American country to join the OECD.
|
Source
: CIA |
|
CORRECT COMPANY NAME |
CFR CORPORACION FARMACEUTICA RECALCINE |
|
MAIN ADDRESS |
Pedro de Valdivia 295, Providencia, Santiago |
|
DEPT/PROV/REGION/STATE |
XIII Región Metropolitana |
|
COUNTRY |
CHILE |
|
TELEPHONE |
(562) 3505200 |
|
CORPORATE E-MAIL |
apino@difrecalcine.cl |
|
COMMENTS |
|
|
As for the present report we must indicate that the name on the order
CORPORATION FARMACEUTICA RECALCINE (CFR) is a corporate name, the correct
name is CFR CORPORACION FARMACEUTICA RECALCINE It has no legal status. Not registered in the Commercial Register It has no Tax Registration. This is the name that is given to a group of companies in the
pharmaceutical item controlled by Mr. Alejandro Westein |
|
|
Chief Executive |
WEINSTEIN MANIEU, ALEJANDRO |
|
Disposition |
REPORT PREPARED FROM OUTSIDE SOURCES. |
|
Payments policy |
Without rating (No payment experience traced) |
|
Number of times that this company was required: 3 |
|
|
LEGAL STATUS |
Economic Group |
|
|
|
CURRENT EXCHANGE RATE (US$) |
Ps$529.89 per USD1.00 |
|
|
|
COMMENTS |
|
||
|
Commercial address: Víctor Chunco. Commercial manager Agustín Eguiguren C. Lawyer Bernardita Araya K.
Research and development manager Luis Yuraszeck B.
Manager division Drugtech Fernando Mariño Manager division K2 Health&Wellness Patricio Mujica B.
Manager division Gynopharm Ana María Bori. Manager division Mediderm Rosanna Vega T. Manager control management Matías Sánchez F.
Human Resources manager Technical management Carlos Olguín R. Technical Director Juan Carlos Lobos D. Production chief Julio Jiménez D.
Management Development, Quality, Pharmaceutical Research and
Regulatory CFR Susana Macchiavello F. Technical director laboratories LAFI Yelda Morales R. Production chief laboratories LAFI |
|||
|
FULL NAMES / COMPANY NAME |
TITLE |
%PART. |
SINCE |
|
WEINSTEIN CRENOVICH, ALEJANDRO |
President |
|
|
|
WEINSTEIN MANIEU, ALEJANDRO |
General Manager |
|
|
|
WEINSTEIN MANIEU, NICOLAS |
Admin. & Finance Manager |
|
|
|
CHUNCO, VICTOR |
Commercial manager |
|
|
|
WEINSTEIN MANIEU, ALEJANDRO |
|
|
TITLE |
General Manager |
|
NATIONALITY |
Chilean |
|
D.O.B. |
10FEB1958 |
|
DOMICILE |
Del Libertador 498, Piso 23, Buenos Aires |
|
PROFESSION |
Commercial Engineer |
|
TAX ID |
20-60333306-4 |
|
BACKGROUND INFORMATION |
Commercial Engineer, Business Administrator and Auditing Accountant
from Pontificia Universidad Católica
de Chile and OPM from Harvard Business School (USA). Member of several boards of directors of pharmaceutical companies in
Latin American, Europe and Southeast Asia, as well as in Chile. |
|
REFERENCES |
|
|
According to source B.C.R.A., he is not reported with any banking debt
over the last 24 months. |
|
ASSOCIATED AS PER OUR
DATABASE TO
|
COMPANY |
TITLE |
TAX REG |
COUNTRY |
|
|
LABORATORIOS NORTHIA S.A.C.I.F. |
President |
30515608210 |
ARGENTINA |
|
|
LABORATORIOS RECALCINE S.A. |
General Manager |
916370008 |
CHILE |
|
|
|
|
|||
|
|
|
|||
|
|
|
||||||||
|
WEINSTEIN MANIEU, NICOLAS |
|||||||||
|
TITLE |
Admin. & Finance Manager |
||||||||
|
|
|
||||||||
|
ASSOCIATED AS PER OUR DATABASE TO |
|||||||||
|
|||||||||
|
|
|
||||||||
|
COMPANY NAME |
COUNTRY |
TAX REG. |
RELATION % |
|
CFR PHARMACEUTICALS S.A. |
CHILE |
76116242 |
Related |
|
INVERSIONES EAST EUROPE PHARMA S.A. |
CHILE |
775303905 |
Related |
|
LABORATORIO LAFI LTDA. |
CHILE |
916370008 |
Related |
|
LABORATORIO RECALCINE S.A. |
CHILE |
(AC) 91637000-8 |
Related |
|
LABORATORIOS RECALCINE S.A. |
CHILE |
(AC) 916370008 |
Related |
|
NOVASALUD.COM S.A. |
CHILE |
969514907 |
Related |
|
RECBEN XENERICS FARMACEUTICA LTDA |
CHILE |
(AC) 78740450-2 |
Related |
|
SIC Classification 5 1 - WHOLESALE TRADE-NON-DURABLE GOODS. (Papers, Perfumes, drugs,
hardware, Groceries, apparel, food, dairy products, beverages.) |
|||||
|
Main activity |
Group of companies in Pharmaceutical field. |
||||
|
SELLING TerritorY |
Domestic market |
||||
|
|||||
|
Disposition |
REPORT PREPARED FROM OUTSIDE SOURCES. |
|
Interviewee(s) |
Fuentes Externas |
|
Information provided |
This report has been developed entirely through external sources,
because we contacted Ms. Ana María Díaz (Corporate Accountant) who declined
to cooperate with our management because it is very sensitive information. |
|
|
|
|
|
|
|
SALES |
US$ 0.00 () |
|
FINANCIAL SITUATION |
UNDETERMINED Public and private sources do not report further details. |
(Confidential Information)
|
TRADE REFERENCES |
|||
|
|
||
Today, 86 years after its founding, Corporación Farmacéutica Recalcine
is the leading company in the pharmaceutical market in Chile. It is constantly
developing projects in biotechnology and clinical studies, under the eaves of
the main educational institutions in Chile and abroad. Aimed to be the first
Latin American laboratory with global presence and own research, Corporación
Farmacéutica Recalcine has the CFR Pharmafuturo Pharmaceutical Complex that was
designed under GMP standars (Good Manufacturing Practice)
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.38 |
|
|
1 |
Rs.102.15 |
|
Euro |
1 |
Rs.85.29 |
INFORMATION DETAILS
|
Report Prepared
by : |
NNA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to
overcome financial difficulties seems comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.